Details of the Drug

General Information of Drug (ID: DMGN4BY)

Drug Name
Flurbiprofen
Synonyms
Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1′ -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Approved [1], [2]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 244.26
Topological Polar Surface Area (xlogp) 4.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
92% of drug becomes completely available to its intended biological destination(s) [4]
Elimination
2.9% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 4.7 hours [5]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 17.545 micromolar/kg/day [7]
Vd
The volume of distribution (Vd) of drug is 14 L [8]
Chemical Identifiers
Formula
C15H13FO2
IUPAC Name
2-(3-fluoro-4-phenylphenyl)propanoic acid
Canonical SMILES
CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
InChI
InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
InChIKey
SYTBZMRGLBWNTM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3394
ChEBI ID
CHEBI:5130
CAS Number
5104-49-4
DrugBank ID
DB00712
TTD ID
D0A1PX
VARIDT ID
DR00587
INTEDE ID
DR0731
ACDINA ID
D00287

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Modulator [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [11]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Rheumatoid arthritis
ICD Disease Classification FA20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.10E-01 -5.91E-02 -3.60E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Flurbiprofen
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Sulfasalazine. Rheumatoid arthritis [FA20] [57]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Dexamethasone. Rheumatoid arthritis [FA20] [58]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Flurbiprofen and Leflunomide. Rheumatoid arthritis [FA20] [59]
Coadministration of a Drug Treating the Disease Different from Flurbiprofen (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Flurbiprofen and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [60]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Repaglinide. Acute diabete complication [5A2Y] [61]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Glibenclamide. Acute diabete complication [5A2Y] [61]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Tolazamide. Acute diabete complication [5A2Y] [61]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Nateglinide. Acute diabete complication [5A2Y] [61]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Glipizide. Acute diabete complication [5A2Y] [61]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Flurbiprofen and Inotersen. Amyloidosis [5D00] [62]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Flurbiprofen and Cilostazol. Arterial occlusive disease [BD40] [63]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Budesonide. Asthma [CA23] [58]
Ofloxacin DM0VQN3 Moderate Additive CNS depression effects by the combination of Flurbiprofen and Ofloxacin. Bacterial infection [1A00-1C4Z] [64]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Kanamycin. Bacterial infection [1A00-1C4Z] [65]
Sparfloxacin DMB4HCT Moderate Additive CNS depression effects by the combination of Flurbiprofen and Sparfloxacin. Bacterial infection [1A00-1C4Z] [64]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Streptomycin. Bacterial infection [1A00-1C4Z] [65]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Flurbiprofen and Gemifloxacin. Bacterial infection [1A00-1C4Z] [64]
Norfloxacin DMIZ6W2 Moderate Additive CNS depression effects by the combination of Flurbiprofen and Norfloxacin. Bacterial infection [1A00-1C4Z] [64]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Flurbiprofen and ABT-492. Bacterial infection [1A00-1C4Z] [64]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Gentamicin. Bacterial infection [1A00-1C4Z] [65]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Netilmicin. Bacterial infection [1A00-1C4Z] [65]
Levofloxacin DMS60RB Moderate Additive CNS depression effects by the combination of Flurbiprofen and Levofloxacin. Bacterial infection [1A00-1C4Z] [64]
Lomefloxacin DMVRH9C Moderate Additive CNS depression effects by the combination of Flurbiprofen and Lomefloxacin. Bacterial infection [1A00-1C4Z] [64]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Etidronic acid. Bone paget disease [FB85] [66]
Risedronate DM5FLTY Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Risedronate. Bone paget disease [FB85] [66]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Flurbiprofen and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [67]
Alpelisib DMEXMYK Moderate Increased metabolism of Flurbiprofen caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [68]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Flurbiprofen and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [63]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Iodipamide. Cholelithiasis [DC11] [69]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Levomilnacipran. Chronic pain [MG30] [70]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Flurbiprofen and Anisindione. Coagulation defect [3B10] [63]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Flurbiprofen and Regorafenib. Colorectal cancer [2B91] [62]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Methoxyflurane. Corneal disease [9A76-9A78] [62]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Flurbiprofen and Ardeparin. Coronary thrombosis [BA43] [71]
Mifepristone DMGZQEF Moderate Decreased metabolism of Flurbiprofen caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [72]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Flurbiprofen caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [73]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Flurbiprofen caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [74]
MK-8228 DMOB58Q Moderate Increased metabolism of Flurbiprofen caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [75]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Flurbiprofen and Danaparoid. Deep vein thrombosis [BD71] [71]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Flurbiprofen and Rivaroxaban. Deep vein thrombosis [BD71] [76]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Flurbiprofen and Sertraline. Depression [6A70-6A7Z] [70]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Flurbiprofen and Vilazodone. Depression [6A70-6A7Z] [70]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Flurbiprofen and Paroxetine. Depression [6A70-6A7Z] [70]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Flurbiprofen and Vortioxetine. Depression [6A70-6A7Z] [70]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Milnacipran. Depression [6A70-6A7Z] [70]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Flurbiprofen and Escitalopram. Depression [6A70-6A7Z] [70]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Flurbiprofen and Desvenlafaxine. Depression [6A70-6A7Z] [70]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Flurbiprofen and Clomipramine. Depression [6A70-6A7Z] [70]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Flurbiprofen and PMID28870136-Compound-49. Discovery agent [N.A.] [77]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Flurbiprofen and Cannabidiol. Epileptic encephalopathy [8A62] [62]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Flurbiprofen when combined with Ethacrynic acid. Essential hypertension [BA00] [78]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Flurbiprofen and Tazemetostat. Follicular lymphoma [2A80] [63]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Flurbiprofen and Avapritinib. Gastrointestinal stromal tumour [2B5B] [62]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Sulfinpyrazone. Gout [FA25] [63]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Flurbiprofen when combined with Bumetanide. Heart failure [BD10-BD1Z] [78]
Hydroflumethiazide DMVPUQI Moderate Antagonize the effect of Flurbiprofen when combined with Hydroflumethiazide. Heart failure [BD10-BD1Z] [78]
Rifapentine DMCHV4I Moderate Increased metabolism of Flurbiprofen caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [79]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Flurbiprofen and Brentuximab vedotin. Hodgkin lymphoma [2B30] [80]
Etravirine DMGV8QU Moderate Decreased metabolism of Flurbiprofen caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [81]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Flurbiprofen and Mipomersen. Hyper-lipoproteinaemia [5C80] [82]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Flurbiprofen and Teriflunomide. Hyper-lipoproteinaemia [5C80] [59]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Flurbiprofen and BMS-201038. Hyper-lipoproteinaemia [5C80] [83]
Indapamide DMGN1PW Moderate Antagonize the effect of Flurbiprofen when combined with Indapamide. Hypertension [BA00-BA04] [78]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Flurbiprofen when combined with Trichlormethiazide. Hypertension [BA00-BA04] [78]
Hydrochlorothiazide DMUSZHD Moderate Antagonize the effect of Flurbiprofen when combined with Hydrochlorothiazide. Hypertension [BA00-BA04] [78]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Flurbiprofen and Dipyridamole. Hypertension [BA00-BA04] [63]
Potassium chloride DMMTAJC Moderate Increased risk of hyperkalemia by the combination of Flurbiprofen and Potassium chloride. Hypo-kalaemia [5C77] [84]
Balsalazide DMO091F Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Balsalazide. Indeterminate colitis [DD72] [57]
PF-06463922 DMKM7EW Moderate Increased metabolism of Flurbiprofen caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [60]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Flurbiprofen and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [85]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Flurbiprofen and Idelalisib. Mature B-cell leukaemia [2A82] [86]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Flurbiprofen and Acalabrutinib. Mature B-cell lymphoma [2A85] [87]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Flurbiprofen and Ibrutinib. Mature B-cell lymphoma [2A85] [88]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Flurbiprofen and Ponatinib. Mature B-cell lymphoma [2A85] [89]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Flurbiprofen caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [62]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Exjade. Mineral absorption/transport disorder [5C64] [90]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Flurbiprofen and Panobinostat. Multiple myeloma [2A83] [60]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Deflazacort. Muscular dystrophy [8C70] [58]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Flurbiprofen and Ruxolitinib. Myeloproliferative neoplasm [2A20] [63]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Flurbiprofen and Dasatinib. Myeloproliferative neoplasm [2A20] [91]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Flurbiprofen and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [92]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Flurbiprofen and Prasugrel. Myocardial infarction [BA41-BA43] [62]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Flurbiprofen and Vorapaxar. Myocardial infarction [BA41-BA43] [93]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Flurbiprofen and Tirofiban. Myocardial infarction [BA41-BA43] [94]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Flurbiprofen and Sibutramine. Obesity [5B80-5B81] [70]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Flurbiprofen and Dexfenfluramine. Obesity [5B80-5B81] [70]
Polythiazide DMCH80F Moderate Antagonize the effect of Flurbiprofen when combined with Polythiazide. Oedema [MG29] [78]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Flurbiprofen caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [95]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Flurbiprofen and MK-4827. Ovarian cancer [2C73] [62]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Aspirin. Pain [MG30-MG3Z] [96]
Hydrocortisone DMGEMB7 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Hydrocortisone. Postoperative inflammation [1A00-CA43] [58]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Epoprostenol. Pulmonary hypertension [BB01] [97]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Flurbiprofen and Iloprost. Pulmonary hypertension [BB01] [97]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Everolimus. Renal cell carcinoma [2C90] [98]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Temsirolimus. Renal cell carcinoma [2C90] [98]
Gatifloxacin DMSL679 Moderate Additive CNS depression effects by the combination of Flurbiprofen and Gatifloxacin. Respiratory infection [CA07-CA4Z] [64]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [58]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Flurbiprofen and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [62]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [58]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Pitolisant. Somnolence [MG42] [62]
Plicamycin DM7C8YV Moderate Increased risk of bleeding by the combination of Flurbiprofen and Plicamycin. Testicular cancer [2C80] [63]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Caplacizumab. Thrombocytopenia [3B64] [63]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Flurbiprofen and Apixaban. Thrombosis [DB61-GB90] [62]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Cangrelor. Thrombosis [DB61-GB90] [63]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Flurbiprofen and Brilinta. Thrombosis [DB61-GB90] [62]
Clopidogrel DMOL54H Moderate Increased risk of bleeding by the combination of Flurbiprofen and Clopidogrel. Thrombosis [DB61-GB90] [63]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Flurbiprofen and Cabozantinib. Thyroid cancer [2D10] [99]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Sirolimus. Transplant rejection [NE84] [98]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Tacrolimus. Transplant rejection [NE84] [98]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Tolbutamide. Type 2 diabetes mellitus [5A11] [61]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Olsalazine. Ulcerative colitis [DD71] [57]
Cinoxacin DM4EWNS Moderate Additive CNS depression effects by the combination of Flurbiprofen and Cinoxacin. Urinary tract infection [GC08] [64]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Plazomicin. Urinary tract infection [GC08] [65]
Nalidixic acid DMRM0JV Moderate Additive CNS depression effects by the combination of Flurbiprofen and Nalidixic acid. Urinary tract infection [GC08] [64]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Flurbiprofen and Betrixaban. Venous thromboembolism [BD72] [100]
⏷ Show the Full List of 112 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 1 E00263 19700 Colorant
Hydrochloric acid E00015 313 Acidulant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Potassium chloride E00074 4873 Tonicity agent
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Edetate disodium E00186 8759 Complexing agent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
⏷ Show the Full List of 22 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Flurbiprofen 100 mg tablet 100 mg Oral Tablet Oral
Flurbiprofen 50 mg tablet 50 mg Oral Tablet Oral
Flurbiprofen Sodium 0.03% solution 0.03% Solution Ophthalmic
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4194).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074358.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
10 Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm. 2015;41(8):1363-7.
11 Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos. 2007 Jul;35(7):1182-7.
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
14 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
15 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
16 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
17 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
18 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
19 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
20 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
21 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
22 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
23 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
24 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
25 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
26 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
27 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
28 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
29 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
30 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
31 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
32 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
33 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
34 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
35 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
36 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
37 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
38 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
39 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
40 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
41 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
42 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
43 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
44 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
45 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
46 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
47 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
48 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
49 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
50 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
51 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
52 Pfizer. Product Development Pipeline. March 31 2009.
53 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
54 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
55 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
56 Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
57 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
58 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
59 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
60 Cerner Multum, Inc. "Australian Product Information.".
61 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
62 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
63 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
64 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
65 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
66 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
67 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
68 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
69 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
70 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
71 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
72 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
73 Cerner Multum, Inc. "Canadian Product Information.".
74 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
75 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
76 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
77 Canadian Pharmacists Association.
78 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
79 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
80 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
81 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
82 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
83 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
84 Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
85 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
86 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
87 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
88 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
89 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
90 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
91 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
92 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
93 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
94 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
95 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
96 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
97 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
98 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
99 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
100 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.